Full video transcriptClick to expand
Auto-generated transcript of @_priss97's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00over 300 pounds and has decided to start taking GLP 1 medication and you guys, your
- 0:05girl just got her first ever pocket in the mail with her prescription. Let's
- 0:09open it together. I promise y'all we're gonna be doing this journey together so
- 0:12let's take a look and see what's inside. Also a quick shot to everybody who has
- 0:15messaged me, slid in my DMs, left a comment, whatever it might have been.
- 0:19Thank you guys so much for your uplifting words, your positivity, your
- 0:24girl was out here kind of crying a little bit because I just did not expect all
- 0:27that and I'm just so grateful to be like on the right side of TikTok and happy
- 0:32all support. I'll further ado let's open up this package. I'm actually going
- 0:36through a telemedicine company called Ammool and when I tell you guys that they
- 0:41are quick with a girl, they are quick. I put in, I signed up for it on the 13th,
- 0:46the 14th my prescription was filled and then I received it today on the 18th. I'm
- 0:51so excited. I know that like I'm talking about it, I was a little bit nervous, not
- 0:55gonna lie but I'm actually starting to get really freaking excited and yeah. Okay so
- 1:01oh my god I feel like I'm unboxing, I don't even know, I'm just crazy. I got
- 1:08tricep-etide, call prep pads, y'all, oh my god it's starting to feel so freaking
- 1:13real I cannot. Okay and then oh my gosh these are syringes, I'm doing it, oh my
- 1:22gosh this is crazy, oh my gosh it's crazy. These are gonna be needles, wow we love that.
- 1:29Okay, with this styrofoam box, okay little ice chest, love that, love that.
- 1:35Oh little message from Ammool, so cute. Let's open the box, play some arm, let's get in.
- 1:45Oh my gosh, oh my gosh. Ice packs, they are reusable so you can put them in your fridge.
- 1:53Oh wow it's in here, oh I'm shook, okay I'm gonna cover my address but it comes in
- 2:05this box right here, I'm shook, I'm shook. Oh my gosh you guys it's like really
- 2:10starting to feel real, it's in my hand, that's crazy, I just can't, I'm so excited.
- 2:17It has instructions on how to do it like the injections which I'm very thankful
- 2:23for because your girls scared, okay. I need my boyfriend's help with this one so
- 2:27let's look into it. Guys that is everything that I received from my package so
- 2:33freaking excited, it's starting to all feel real, 40's until I start my first
- 2:37injection ever, it's all hitting me right now, okay. Looking to start your GLP1
- 2:41journey, feel free to message me, comment, click in the link in my bio,
- 2:46get my link tree and it's gonna be that very first little box it's gonna say
- 2:50the Ambles, I might glue tie, I'll turn it up a tie, the countdown begin.
Tirzepatide for weight loss: separating the hype from the data
Quick answer
The creator is a self-described individual over 300 pounds who received compounded tirzepatide through a telehealth platform approximately five days after signing up, without disclosing whether a physician reviewed her labs, cardiovascular history, or contraindications like a personal or family history of medullary thyroid carcinoma. Tirzepatide is a dual GIP and GLP-1 receptor agonist with demonstrated efficacy for chronic weight management in adults with obesity, but the compounded formulation she received has not undergone FDA review for safety, potency, or bioequivalence to brand-name Zepbound. Viewers replicating her path should verify the prescribing clinician's licensure, the compounding pharmacy's accreditation status, and whether the product contains the same active salt form as the FDA-approved drug.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide for weight loss: separating the hype from the data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Tirzepatide for weight loss: separating the hype from the data" from PRISS • My Glowup Era 🤍. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is a self-described individual over 300 pounds who received compounded tirzepatide through a telehealth platform approximately five days after signing up, without disclosing whether a physician reviewed her labs, cardiovascular history, or contraindications like a personal or family history of medullary thyroid carcinoma.
The reason this review is not generic is the source wording and the canonical claim label "glp1 thank you so much join amble it s starting to feel real eeee." In this clip, the useful excerpt is: "over 300 pounds and has decided to start taking GLP 1 medication and you guys, your girl just got her first ever pocket in the mail with her prescription." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is a self-described individual over 300 pounds who received compounded tirzepatide through a telehealth platform approximately five days after signing up, without disclosing whether a physician reviewed her labs, cardiovascular history, or contraindications like a personal or family history of medullary thyroid carcinoma.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is a self-described individual over 300 pounds who received compounded tirzepatide through a telehealth platform approximately five days after signing up, without disclosing whether a physician reviewed her labs, cardiovascular history, or contraindications like a personal or family history of medullary thyroid carcinoma. Tirzepatide is a dual GIP and GLP-1 receptor agonist with demonstrated efficacy for chronic weight management in adults with obesity, but the compounded formulation she received has not undergone FDA review for safety, potency, or bioequivalence to brand-name Zepbound. Viewers replicating her path should verify the prescribing clinician's licensure, the compounding pharmacy's accreditation status, and whether the product contains the same active salt form as the FDA-approved drug.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed 20.9% average body weight loss with brand-name tirzepatide over 72 weeks, but that data does not automatically extend to compounded versions
- The FDA declared the tirzepatide shortage resolved in early 2025 and began enforcement actions against compounding pharmacies continuing to produce it outside approved channels
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed 20.9% average body weight loss with brand-name tirzepatide over 72 weeks, but that data does not automatically extend to compounded versions
- The FDA declared the tirzepatide shortage resolved in early 2025 and began enforcement actions against compounding pharmacies continuing to produce it outside approved channels
- Compounded tirzepatide may use tirzepatide base rather than tirzepatide hydrochloride, the salt form in FDA-approved Zepbound, and the FDA has flagged this difference as a potential safety concern with no published bioequivalence data
- 503B outsourcing facilities are subject to FDA inspection and Current Good Manufacturing Practice standards; 503A pharmacies are not routinely inspected, making accreditation status a meaningful question to ask
- One-day prescription turnaround times at telehealth platforms are possible but do not confirm that a thorough clinical evaluation occurred, including contraindication screening for thyroid cancer history or pancreatitis risk
- FTC guidelines require TikTok creators to clearly disclose paid partnerships or referral compensation when directing audiences to commercial platforms; no disclosure is present in this video
- A BMI above 30, which the creator's described weight would likely reflect, meets the FDA-labeled prescribing threshold for tirzepatide, but clinical suitability requires individual evaluation beyond weight alone
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @_priss97 actually say?
She said she's "over 300 pounds" and just received her first prescription from a telehealth company she calls "Ammool" (almost certainly Amble). She unboxed compounded tirzepatide along with alcohol prep pads, syringes, and needles, noting the package arrived within five days of signing up. She's inviting followers to message her or click her bio link to start their own GLP-1 journey, and she's using affiliate-style hashtags for Amble throughout.
This is an unboxing video, not a medical explainer. She makes no direct efficacy claims about the drug itself, doesn't cite a dose, and doesn't say tirzepatide cured or treats any specific disease. What she does do is act as a de facto recruiter for Amble, complete with a referral link, which is worth knowing before you take anything in this video at face value.
Does the science back this up?
Tirzepatide itself has strong clinical backing. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants lost an average of 20.9% of body weight over 72 weeks on the highest dose. That's real, peer-reviewed data on brand-name tirzepatide (Zepbound). The compounded version she received is a different story.
Compounded tirzepatide is not FDA-approved. It was permitted under shortage rules when brand-name Zepbound faced supply constraints, but the FDA has since moved to end that shortage designation. The compound may contain tirzepatide base rather than tirzepatide hydrochloride (the salt used in Zepbound), and as of early 2025 the FDA explicitly flagged this distinction as a safety and efficacy concern. There are no published randomized controlled trials on compounded tirzepatide's bioavailability, purity, or consistency across compounding pharmacies. The drug works. What's in her vial is less certain.
What did they get wrong (or right)?
She got the enthusiasm right, and honestly the five-day turnaround from signup to delivery is accurate to how many compounding telehealth platforms operate right now. She correctly identified what was in the package, needles, syringes, prep pads, and the medication itself, without making false efficacy promises. That's better than a lot of GLP-1 content on TikTok.
What she got wrong, or at least incomplete: she never tells viewers this is compounded, not brand-name Zepbound. That distinction matters. She says "tricep-etide" (tirzepatide) as if it's the same product you'd get at a pharmacy filling a Zepbound script. It isn't. Compounded drugs skip the FDA approval process. Potency can vary between batches and between pharmacies. She also positions herself as a resource, "feel free to message me," for people starting their own GLP-1 journey, which is an informal medical guidance role she's not qualified to fill, regardless of how well-intentioned she is.
What should you actually know?
If you're over 300 pounds and considering a GLP-1, the data genuinely supports that conversation with a real clinician. A BMI above 30, or above 27 with a weight-related condition, is the standard prescribing threshold for tirzepatide under current FDA labeling. That part of her situation checks out on paper.
But the sourcing question is non-trivial. The FDA's 2025 guidance warned that some compounded tirzepatide products use an untested salt form, and that patients and providers may not know the difference. The American Society of Health-System Pharmacists has documented quality failures at some 503A compounding pharmacies, including incorrect concentrations. Before you click anyone's bio link and sign up, ask the telehealth platform specifically which form of tirzepatide they compound, which pharmacy fills it, and whether that pharmacy is 503A or 503B accredited. A 503B outsourcing facility is subject to FDA inspection. A 503A pharmacy is not, at least not routinely. That is not a small distinction when you're injecting something weekly.
- Tirzepatide's clinical data comes from brand-name Zepbound trials, not compounded versions
- Ask any compounding platform whether they use tirzepatide base or tirzepatide hydrochloride
- Telehealth prescribing speed is real, but speed is not the same as safety review
- The FDA began enforcement actions against compounded tirzepatide in early 2025 after declaring the shortage resolved
- No affiliate link from a TikToker replaces a conversation with a physician who knows your full medical history
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
PRISS • My Glowup Era 🤍 · TikTok creator
64.8K views on this video
Thank you so much @Join Amble ✨🧡 it’s starting to feel real! EEEEEK! If you’re wanting to start your journey check the 🔗 in my bio or message me with any questions 🥰 #ambleptnr #amble #joinamble #glp1 #tirzepatide #glp1forweightloss #newjourney #weightloss
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed 20.9% average body?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed 20.9% average body weight loss with brand-name tirzepatide over 72 weeks, but that data does not automatically extend to compounded versions
What does the video say about the fda declared the tirzepatide shortage resolved in early 2025?
The FDA declared the tirzepatide shortage resolved in early 2025 and began enforcement actions against compounding pharmacies continuing to produce it outside approved channels
What does the video say about compounded tirzepatide may use tirzepatide base rather than tirzepatide hydrochloride,?
Compounded tirzepatide may use tirzepatide base rather than tirzepatide hydrochloride, the salt form in FDA-approved Zepbound, and the FDA has flagged this difference as a potential safety concern with no published bioequivalence data
What does the video say about 503b outsourcing facilities?
503B outsourcing facilities are subject to FDA inspection and Current Good Manufacturing Practice standards; 503A pharmacies are not routinely inspected, making accreditation status a meaningful question to ask
What does the video say about one-day prescription turnaround times at telehealth platforms?
One-day prescription turnaround times at telehealth platforms are possible but do not confirm that a thorough clinical evaluation occurred, including contraindication screening for thyroid cancer history or pancreatitis risk
What does the video say about ftc guidelines require tiktok creators to clearly disclose paid partnerships?
FTC guidelines require TikTok creators to clearly disclose paid partnerships or referral compensation when directing audiences to commercial platforms; no disclosure is present in this video
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by PRISS • My Glowup Era 🤍, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.